HC Wainwright Cuts Earnings Estimates for Alto Neuroscience

Alto Neuroscience, Inc. (NYSE:ANRO) – Research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for shares of Alto Neuroscience in a report released on Monday, October 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.68) for the quarter, down from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($2.82) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.80) EPS, FY2027 earnings at ($3.17) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($4.01) EPS and FY2030 earnings at ($3.51) EPS.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08.

ANRO has been the topic of a number of other reports. BTIG Research raised their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Zacks Research raised Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Finally, Wedbush increased their target price on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.88.

Alto Neuroscience Trading Up 7.3%

Shares of NYSE ANRO opened at $24.48 on Wednesday. The company’s 50 day simple moving average is $29.98 and its 200 day simple moving average is $26.32. Alto Neuroscience has a fifty-two week low of $9.73 and a fifty-two week high of $37.48. The firm has a market capitalization of $960.64 million, a P/E ratio of -10.12 and a beta of 1.31. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its stake in shares of Alto Neuroscience by 48,581.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock valued at $137,000 after purchasing an additional 5,344 shares during the period. GK Wealth Management LLC bought a new stake in shares of Alto Neuroscience in the second quarter valued at about $226,000. Revisor Wealth Management LLC acquired a new position in shares of Alto Neuroscience during the first quarter worth about $385,000. The Manufacturers Life Insurance Company acquired a new position in shares of Alto Neuroscience during the first quarter worth about $534,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Alto Neuroscience during the first quarter worth about $538,000.

Insider Buying and Selling

In related news, CFO Nicholas Smith sold 24,056 shares of the company’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the completion of the transaction, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $621,229.20. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.25% of the company’s stock.

Trending Headlines about Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright raised its price target on Alto Neuroscience (ANRO) to $60 from $55 while maintaining its Buy rating, signaling increased confidence in the company’s outlook. HC Wainwright Adjusts Alto Neuroscience Price Target to $60 From $55, Maintains Buy Rating
• Positive Sentiment: The analyst raised EPS forecasts for 2027, including Q1 to $(0.76) from $(0.93), Q2 to $(0.79) from $(0.97), Q3 to $(0.82) from $(1.00), and Q4 to $(0.80) from $(0.96). The full-year 2027 estimate also improved to $(3.17) from $(3.87), suggesting expectations for narrower losses.
• Positive Sentiment: HC Wainwright lifted its FY2028 EPS forecast to $(4.00) from $(4.39), another indication that projected losses may be less severe than previously expected. Alto Neuroscience Stock Gets Price Target Boost from HC Wainwright
• Neutral Sentiment: The revisions remain forecasts rather than reported results. HC Wainwright still expects Alto Neuroscience to post losses, including $(2.82) EPS for fiscal 2026, compared with the current consensus estimate of $(2.68).
• Negative Sentiment: Longer-term estimates were reduced for FY2029, to $(4.01) from $(3.25), and FY2030, to $(3.51) from $(1.29). These cuts highlight continued uncertainty surrounding the company’s path to profitability, despite the unchanged Buy rating.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.

Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.